Skip to content
lifestyle.utv.ie
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HCW Biologics Inc.
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
November 16, 2026
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
November 9, 2026
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
November 6, 2026
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
November 5, 2026
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
October 9, 2026
HCW Biologics Announces Pricing of $1.5 Million Private Placement
September 24, 2026
HCW11-006 CAR-T Reagent Commercialized by HCW Biologics & Akron Biotech
September 8, 2026
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
September 2, 2026
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
August 25, 2026
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
August 14, 2026
1
2
Next Page
→